Glycoprotein-C-gene-deleted recombinant infectious laryngotracheitis virus expressing a genotype VII Newcastle disease virus fusion protein protects against virulent infectious laryngotracheitis virus and Newcastle disease virus
- PMID: 33011664
- DOI: 10.1016/j.vetmic.2020.108835
Glycoprotein-C-gene-deleted recombinant infectious laryngotracheitis virus expressing a genotype VII Newcastle disease virus fusion protein protects against virulent infectious laryngotracheitis virus and Newcastle disease virus
Abstract
To develop an alternative vectored vaccine against both Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV), the glycoprotein C (gC) gene was first deleted from an avirulent ILTV. Based on this gC-deleted ILTV mutant, a recombinant ILTV expressing the fusion protein (F) of a genotype VII NDV (designated ILTV-ΔgC-F) was then constructed. Expression of the NDV F protein in ILTV-ΔgC-F-infected LMH cells was examined with an immunofluorescence assay and western blotting. The F gene was stably maintained in the genome of ILTV-ΔgC-F and the F protein was stably expressed. Compared with the parental virus, ILTV-ΔgC-F demonstrated an increased penetration capacity in vitro, and an increased replication rate in vitro and in vivo. Both the parental virus and ILTV-ΔgC-F were avirulent in chickens. Vaccination of specific-pathogen-free chickens with ILTV-ΔgC-F induced ILTV-specific antibodies, detected with an enzyme-linked immunosorbent assay (ELISA), and provided complete clinical protection against virulent ILTV, although viral shedding and replication were detected in the respiratory tract in the early stage of infection in a very small number of birds. Vaccination with ILTV-ΔgC-F also provided significant protection against challenge with a virulent genotype VII NDV, although the level of NDV-specific antibodies detected with an ELISA was low. Notably, the numbers of birds that were positive for the virulent genotype VII NDV and the replication of the challenge virus NDV in selected target tissues were significantly lower in the ILTV-ΔgC-F-vaccinated chickens than in the control birds. Our results indicate that ILTV-ΔgC-F has potential utility as a bivalent candidate vaccine against both infectious laryngotracheitis and Newcastle disease.
Keywords: Bivalent vaccine candidate; Genotype VII; Infectious laryngotracheitis virus; Newcastle disease virus; gC.
Copyright © 2020 Elsevier B.V. All rights reserved.
Similar articles
-
Recombinant infectious laryngotracheitis virus expressing Newcastle disease virus F protein protects chickens against infectious laryngotracheitis virus and Newcastle disease virus challenge.Vaccine. 2018 Dec 18;36(52):7975-7986. doi: 10.1016/j.vaccine.2018.11.008. Epub 2018 Nov 15. Vaccine. 2018. PMID: 30448332
-
Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies.Vaccine. 2017 Feb 1;35(5):789-795. doi: 10.1016/j.vaccine.2016.12.038. Epub 2017 Jan 2. Vaccine. 2017. PMID: 28052812
-
A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens.Vaccine. 2014 Jun 12;32(28):3555-63. doi: 10.1016/j.vaccine.2014.04.068. Epub 2014 Apr 30. Vaccine. 2014. PMID: 24793943
-
Immune responses to infectious laryngotracheitis virus.Dev Comp Immunol. 2013 Nov;41(3):454-62. doi: 10.1016/j.dci.2013.03.022. Epub 2013 Apr 6. Dev Comp Immunol. 2013. PMID: 23567343 Review.
-
Current and future vaccines and vaccination strategies against infectious laryngotracheitis (ILT) respiratory disease of poultry.Vet Microbiol. 2017 Jul;206:157-162. doi: 10.1016/j.vetmic.2016.12.023. Epub 2016 Dec 24. Vet Microbiol. 2017. PMID: 28057380 Review.
Cited by
-
Construction and Evaluation of the Immunogenicity and Protective Efficacy of Recombinant Replication-Deficient Human Adenovirus-5 Expressing Genotype VII Newcastle Disease Virus F Protein and Infectious Bursal Disease Virus VP2 Protein.Vaccines (Basel). 2023 May 31;11(6):1051. doi: 10.3390/vaccines11061051. Vaccines (Basel). 2023. PMID: 37376440 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous